Trials / Active Not Recruiting
Active Not RecruitingNCT07252908
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQC3721 Inhalation Powder in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 195 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of TQC3721 inhalation powder in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQC3721 inhalation powder | TQC3721 inhalation powder is target inhibitor. |
| DRUG | Placebo for TQC3721 inhalation powder | Placebo for TQC3721 inhalation powder. |
Timeline
- Start date
- 2025-12-22
- Primary completion
- 2026-05-01
- Completion
- 2026-06-01
- First posted
- 2025-11-28
- Last updated
- 2026-04-06
Locations
29 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07252908. Inclusion in this directory is not an endorsement.